Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.
Simonneau G, D'Armini AM, Ghofrani HA, Grimminger F, Jansa P, Kim NH, Mayer E, Pulido T, Wang C, Colorado P, Fritsch A, Meier C, Nikkho S, Hoeper MM. Simonneau G, et al. Among authors: pulido t. Lancet Respir Med. 2016 May;4(5):372-80. doi: 10.1016/S2213-2600(16)30022-4. Epub 2016 Apr 8. Lancet Respir Med. 2016. PMID: 27067478 Clinical Trial.
Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Rubin LJ, et al. Among authors: pulido t. N Engl J Med. 2002 Mar 21;346(12):896-903. doi: 10.1056/NEJMoa012212. N Engl J Med. 2002. PMID: 11907289 Free article. Clinical Trial.
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.
Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, Espinola-Zavaleta N, Rocchi G, Manes A, Frantz R, Kurzyna M, Nagueh SF, Barst R, Channick R, Dujardin K, Kronenberg A, Leconte I, Rainisio M, Rubin L. Galiè N, et al. Among authors: pulido t. J Am Coll Cardiol. 2003 Apr 16;41(8):1380-6. doi: 10.1016/s0735-1097(03)00121-9. J Am Coll Cardiol. 2003. PMID: 12706935 Free article. Clinical Trial.
Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G; SERAPHIN Investigators. Pulido T, et al. N Engl J Med. 2013 Aug 29;369(9):809-18. doi: 10.1056/NEJMoa1213917. N Engl J Med. 2013. PMID: 23984728 Free article. Clinical Trial.
Macitentan and pulmonary arterial hypertension.
Pulido T, Rubin LJ, Simonneau G. Pulido T, et al. N Engl J Med. 2014 Jan 2;370(1):82-3. doi: 10.1056/NEJMc1313112. N Engl J Med. 2014. PMID: 24382071 No abstract available.
Effect of macitentan on hospitalizations: results from the SERAPHIN trial.
Channick RN, Delcroix M, Ghofrani HA, Hunsche E, Jansa P, Le Brun FO, Mehta S, Pulido T, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Galiè N. Channick RN, et al. Among authors: pulido t. JACC Heart Fail. 2015 Jan;3(1):1-8. doi: 10.1016/j.jchf.2014.07.013. Epub 2014 Nov 11. JACC Heart Fail. 2015. PMID: 25457902 Free article. Clinical Trial.
Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension.
Benza RL, Gomberg-Maitland M, Demarco T, Frost AE, Torbicki A, Langleben D, Pulido T, Correa-Jaque P, Passineau MJ, Wiener HW, Tamari M, Hirota T, Kubo M, Tiwari HK. Benza RL, et al. Among authors: pulido t. Am J Respir Crit Care Med. 2015 Dec 1;192(11):1345-54. doi: 10.1164/rccm.201501-0196OC. Am J Respir Crit Care Med. 2015. PMID: 26252367 Free PMC article.
Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN.
Simonneau G, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BK, Sitbon O, Souza R, Torbicki A, Rubin LJ. Simonneau G, et al. Among authors: pulido t. Eur Respir J. 2015 Dec;46(6):1711-20. doi: 10.1183/13993003.00364-2015. Epub 2015 Oct 22. Eur Respir J. 2015. PMID: 26493786 Free PMC article. Clinical Trial.
Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.
Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani HA, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O. Mehta S, et al. Among authors: pulido t. Chest. 2017 Jan;151(1):106-118. doi: 10.1016/j.chest.2016.08.1473. Epub 2016 Sep 23. Chest. 2017. PMID: 27671974 Free article. Clinical Trial.
SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.
Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani HA, Le Brun FO, Mehta S, Perchenet L, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A. Galiè N, et al. Among authors: pulido t. Eur Heart J. 2017 Apr 14;38(15):1147-1155. doi: 10.1093/eurheartj/ehx025. Eur Heart J. 2017. PMID: 28329315 Free PMC article. Clinical Trial.
80 results